ASND vs GRFS
Ascendis Pharma A/S and Grifols SA, side by side — 10 fiscal years reported in EUR, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | ASND | GRFS |
|---|---|---|
| Revenue | €720.1M | €7.2B |
| Net income | €-228.0M | €156.9M |
| Gross margin | 86.8% | 38.7% |
| Net margin | −31.7% | 2.2% |
| Return on equity | — | 2.8% |
| Diluted EPS | −€3.76 | €0.23 |
| Dividend / share | — | — |
| Payout ratio | — | 0.6% |
| Free cash flow | €-469.8M | €669.6M |
| Equity | — | €5.9B |
| Net debt / equity | — | −0.42× |
| Current ratio | 1.04× | 2.66× |
| Revenue CAGR 5y | 153.0% | 7.2% |
| Profit CAGR 5y | — | −24.2% |
GRFS bills 10.0× the revenue of ASND, and ASND closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | ASND | GRFS |
|---|---|---|
| FY2024 | €363.6M | €7.2B |
| FY2023 | €266.7M | €6.6B |
| FY2022 | €51.2M | €6.1B |
| FY2021 | €7.8M | €4.9B |
| FY2020 | €7.0M | €5.3B |
| FY2019 | €13.4M | €5.1B |
| FY2018 | €10.6M | €4.5B |
| FY2017 | €1.5M | €4.3B |
| FY2016 | €4.6M | €4.0B |
| FY2015 | €8.1M | €3.9B |
Net income by year
Bottom line
| Fiscal year | ASND | GRFS |
|---|---|---|
| FY2024 | €-378.1M | €156.9M |
| FY2023 | €-481.4M | €42.3M |
| FY2022 | €-583.2M | €185.0M |
| FY2021 | €-383.6M | €188.7M |
| FY2020 | €-419.0M | €618.5M |
| FY2019 | €-218.0M | €625.1M |
| FY2018 | €-130.1M | €596.6M |
| FY2017 | €-123.9M | €662.7M |
| FY2016 | €-68.5M | €545.5M |
| FY2015 | €-32.9M | €532.1M |
Advertisement
AdSense · Rectangle 336×280